SIRPA and cancer: As a small molecule inhibitor, RRx-001 can polarize the low phagocytic M2 phenotype of tumor-associated macrophages to a high phagocytic M1 phenotype, and can decrease the levels of CD47 on cancer cells and SIRPα on macrophages simultaneously (48).